Biotech News
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
ir.replimune.com2026-05-06 14:54 EST
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass. , Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the